Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBIN melanoma sequencing trial
NL-OMON55892Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, binimetinib, ipilimumab and nivolumab in melanoma, cutaneous melanoma (CM) and mucosal melanoma (MM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Nov 2019; status: recruiting.
02
Drugs
03
Conditions
melanomacutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NL-OMON55892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55892.